Homepage500660 • BOM
add
GlaxoSmithKline Pharmaceuticals Ltd
Vorige slotkoers
₹ 3.298,05
Dag-range
₹ 3.272,00 - ₹ 3.362,55
Jaar-range
₹ 1.924,30 - ₹ 3.515,95
Beurswaarde
564,55 mld. INR
Gem. volume
8,93K
Koers/winst
60,80
Dividendrendement
1,26%
Primaire beurs
NSE
Marktnieuws
Financiële informatie
Resultatenrekening
Opbrengst
Netto inkomsten
| (INR) | mrt 2025info | Wijziging j-o-j |
|---|---|---|
Opbrengst | 9,74 mld. | 4,79% |
Bedrijfskosten | 2,77 mld. | -8,47% |
Netto inkomsten | 2,63 mld. | 35,17% |
Netto winstmarge | 26,98 | 28,97% |
Winst per aandeel | 54,52 | — |
EBITDA | 3,32 mld. | 32,98% |
Effectief belastingtarief | 26,69% | — |
Balans
Totale activa
Totale passiva
| (INR) | mrt 2025info | Wijziging j-o-j |
|---|---|---|
Contanten en kortetermijnbeleggingen | 24,98 mld. | 34,54% |
Totale activa | 41,08 mld. | 15,50% |
Totale passiva | 21,57 mld. | 21,24% |
Totaal aandelenvermogen | 19,51 mld. | — |
Uitstaande aandelen | 169,41 mln. | — |
Koers-boekwaardeverhouding | 28,63 | — |
Rendement op activa | — | — |
Rendement op kapitaal | 44,16% | — |
Kasstroom
Nettomutatie in liquide middelen
| (INR) | mrt 2025info | Wijziging j-o-j |
|---|---|---|
Netto inkomsten | 2,63 mld. | 35,17% |
Operationele kasstroom | — | — |
Kasstroom uit beleggingen | — | — |
Kasstroom uit financiering | — | — |
Nettomutatie in liquide middelen | — | — |
Vrije kasstroom | — | — |
Over
GlaxoSmithKline Pharmaceuticals Ltd is an Indian research-based pharmaceutical and healthcare company, and a subsidiary of GSK. The company's product portfolio includes prescription medicines and vaccines. Its prescription medicines range across therapeutic areas such as anti-infectives, dermatology, gynaecology, diabetes, oncology, cardiovascular disease, and respiratory diseases. It also offers a range of vaccines, for the prevention of hepatitis A, hepatitis B, invasive disease caused by H, influenzae, chickenpox, diphtheria, pertussis, tetanus, rotavirus, cervical cancer, and others. Wikipedia
Opgericht
13 nov 1924
Website
Werknemers
3.113
